ADMA Biologics Inc · Q1 2020 earnings

Briefing

ADMA Biologics reported first quarter 2020 financial results, achieving a 189% increase in total revenues compared to the first quarter of 2019 and strengthening its balance sheet through a successful public offering.

ADMA Biologics reported a strong first quarter in 2020, with total revenues increasing by 189% compared to the same period in 2019. The company's net loss increased due to investments in production capacity and commercial infrastructure. ADMA ended the quarter with a strong cash position due to a successful public offering.

• Total revenues for Q1 2020 were $10.2 million, a 189% increase compared to Q1 2019.
• The revenue increase was primarily driven by increased sales and production of immunoglobulin products from the Boca Facility.
• Consolidated net loss for Q1 2020 was $19.2 million, or $(0.26) per share, compared to a net loss of $13.1 million, or $(0.28) per share, for Q1 2019.
• ADMA completed an underwritten public offering in February 2020, resulting in net proceeds of $88.7 million, strengthening the balance sheet.

Headline financials

Revenue & EPS history

ADMA anticipates positive changes due to increased raw material plasma collection, expanded production capacity, and aseptic filling capability, potentially lowering costs, improving gross margins, and providing more flexibility.